For the year ending 2025-12-31, COGT had $214,263K increase in cash & cash equivalents over the period. -$265,998K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -328,937 |
| Depreciation expense | 2,564 |
| Stock-based compensation expense | 46,079 |
| Amortization of right-of-use operating lease assets | 2,019 |
| Change in fair value of cvr liability | 0 |
| Net amortization (accretion) of premiums (discounts) on marketable securities | 1,962 |
| Loss on disposal of property and equipment | 0 |
| Amortization of debt discount and issuance costs | 601 |
| Loss on debt extinguishment | -7,181 |
| Prepaid expenses and other current assets | 195 |
| Other assets | -1,561 |
| Accounts payable | -2,509 |
| Accrued expenses and other current liabilities | 10,686 |
| Operating lease liability | -1,565 |
| Other liabilities | 33 |
| Net cash used in operating activities | -264,444 |
| Purchases of property and equipment | 1,554 |
| Purchases of marketable securities | 687,171 |
| Maturities and sales of marketable securities | 289,199 |
| Net cash provided by (used in) investing activities | -399,526 |
| Proceeds from long-term debt | 49,291 |
| Repayment of long-term debt | 54,635 |
| Proceeds from convertible senior notes | 223,100 |
| Payment of debt issuance costs | 2,622 |
| Proceeds from issuance of common stock in public offerings, net of offering costs-IPOOne | 539,776 |
| Proceeds from issuance of common stock in public offerings, net of offering costs-IPOTwo | 0 |
| Proceeds from issuance of common stock under atm, net of issuance costs of 4.9 million | 159,323 |
| Proceeds from issuance of common stock and series b non-voting convertible preferred stock in connection with the private placement, net of offering costs 11.7 million | 0 |
| Taxes paid related to net share settlement of equity awards | 48,896 |
| Proceeds from issuance of common stock upon stock option exercises | 11,546 |
| Proceeds from issuance of stock from employee stock purchase plan | 1,350 |
| Net cash provided by financing activities | 878,233 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 214,263 |
| Cash and cash equivalents at beginning of period | 98,165 |
| Cash and cash equivalents at end of period | 312,428 |
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)